HYAL-BV 5200: Will begin a Canadian Phase II dose-ranging trial in 36 patients

Hyal Pharmaceutical Corp. (HYALF), Mississauga, Ontario Product: HYAL-BV 5200 (iv hyaluronan product) Indication: Restenosis following angioplasty Status: Will begin a Canadian Phase II dose-ranging t...